Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer (SHINE)

January 16, 2017 updated by: AstraZeneca

A Randomised Open-Label Phase II Study to Assess the Efficacy & Safety of AZD4547 Monotherapy Versus Paclitaxel in Patients With Advanced Gastric Adenocarcinoma (Inc. Adenocarcinoma of the Lower Third of the Oesophagus or the Gastro-Oesophageal Junction)With FGFR2 Polysomy or Gene Amplification.

The purpose of this study is to assess the efficacy, safety and tolerability of AZD4547 compared with paclitaxel in patients with advanced gastric or lower-oesophageal cancer whose tumours are found to have FGFR2 polysomy or gene amplification.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

A Randomised Open-Label Phase IIa Study to Assess the Efficacy and Safety of AZD4547 monotherapy versus paclitaxel in Patients with Advanced Gastric or Gastro-oesophageal Junction Cancer with FGFR2 Polysomy or Gene Amplification (SHINE study). Patients were to be assigned to strata by FGFR2 status of: polysomy, low or high gene amplification.

Study Type

Interventional

Enrollment (Actual)

960

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Brussels (Anderlecht), Belgium
        • Research Site
      • Brussels (Woluwé-St-Lambert), Belgium
        • Research Site
      • Leuven, Belgium
        • Research Site
      • Liege, Belgium
        • Research Site
  • Bulgaria
      • Plovdiv, Bulgaria
        • Research Site
      • Sofia, Bulgaria
        • Research Site
      • Vratza, Bulgaria
        • Research Site
  • Canada
    • New Brunswick
      • Fredericton, New Brunswick, Canada
        • Research Site
    • Ontario
      • Toronto, Ontario, Canada
        • Research Site
  • Czech Republic
      • Brno, Czech Republic
        • Research Site
      • Olomouc, Czech Republic
        • Research Site
      • Praha 2, Czech Republic
        • Research Site
  • France
      • Saint Cloud, France
        • Research Site
      • Villejuif, France
        • Research Site
  • Germany
      • Hamburg, Germany
        • Research Site
      • Mainz, Germany
        • Research Site
  • Hungary
      • Budapest, Hungary
        • Research Site
      • Debrecen, Hungary
        • Research Site
      • Nyíregyháza, Hungary
        • Research Site
  • India
      • Bangalore, India
        • Research Site
      • Chennai, India
        • Research Site
      • Hyderabad, India
        • Research Site
      • Nagpur, India
        • Research Site
      • Pune, India
        • Research Site
      • Vellore, India
        • Research Site
  • Italy
      • Ancona, Italy
        • Research Site
      • Milano, Italy
        • Research Site
      • Pisa, Italy
        • Research Site
      • Roma, Italy
        • Research Site
  • Japan
      • Chiba-shi, Japan
        • Research Site
      • Chuo-ku, Japan
        • Research Site
      • Koto-ku, Japan
        • Research Site
      • Nagoya-shi, Japan
        • Research Site
      • Sapporo-shi, Japan
        • Research Site
      • Takatsuki-shi, Japan
        • Research Site
  • Korea, Republic of
      • Anyang-si, Korea, Republic of
        • Research Site
      • Daegu, Korea, Republic of
        • Research Site
      • Hwasun-gun, Korea, Republic of
        • Research Site
      • Jeonju-si, Korea, Republic of
        • Research Site
      • Seongnam-si, Korea, Republic of
        • Research Site
      • Seoul, Korea, Republic of
        • Research Site
  • Romania
      • Brasov, Romania
        • Research Site
      • Cluj Napoca, Romania
        • Research Site
  • Spain
      • A Coruña, Spain
        • Research Site
      • Barcelona, Spain
        • Research Site
      • Madrid, Spain
        • Research Site
      • Oviedo, Spain
        • Research Site
      • Santander, Spain
        • Research Site
      • Sevilla, Spain
        • Research Site
  • Taiwan
      • Keelung, Taiwan
        • Research Site
      • Taichung, Taiwan
        • Research Site
      • Taipei, Taiwan
        • Research Site
      • Taoyuan, Taiwan
        • Research Site
  • Ukraine
      • Kharkiv, Ukraine
        • Research Site
      • Lviv, Ukraine
        • Research Site
  • United Kingdom
      • Aberdeen, United Kingdom
        • Research Site
      • London, United Kingdom
        • Research Site
      • Maidstone, United Kingdom
        • Research Site
      • Manchester, United Kingdom
        • Research Site
      • Sutton, United Kingdom
        • Research Site
      • Wolverhampton, United Kingdom
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 130 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Female or male aged 25 or over
  • Histological diagnosis of locally advanced or metastatic gastro adenocarcinoma (including adenocarcinoma of the lower third of the oesophagus or the gastro oesophageal junction )
  • Radiographically confirmed progression after 1 prior chemotherapy or chemoradiotherapy for gastric cancer. Suitable for and expected to benefit from paclitaxel monotherapy.
  • At least one lesion, not previously irradiated, that has baseline at least 10mm in the longest diameter for non nodal lesions and is assessed by Computerised Tomography (CT) or Magnetic Resonance Imaging (MRI)
  • Provision of either an archival tumour sample or a fresh tumour sample for confirmation of FGFR2 polysomy/gene amplification

Exclusion Criteria:

  • Prior exposure to AZD4547 or history of hypersensitivity other drugs similar in structure or class to AZD4547. Hypersensitivity to paclitaxel or formulated in cremophor EL (polyoxyethylated castor oil)
  • Prior taxane treatment for gastric cancer with the exception of adjuvant/neo-adjuvant therapy given > 6 months; Major surgery, radiotherapy with wide field of radiation or any cancer treatment within 4 weeks before the first dose of the study treatment
  • With the exception of alopecia, any unresolved toxicities from prior therapy with a Common Terminology Criteria for AE (CTCAE) grade >1 at the time of starting study treatment.
  • Blood and Echocardiogram (ECG) readings that are deemed to be abnormal by falling outside of the reference ranges in the protocol inclusion/exclusion section.
  • Taking other regular medication that are predicted to interact with AZD4547 due to their route of metabolism.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: AZD4547
AZD4547 taken orally in tablet formation, 80mg b.d., in a 2 week on, 1 week off schedule
Drug: AZD4547
Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
ACTIVE_COMPARATOR: Paclitaxel
Paclitaxel - 80mg/m² as a 1 hour infusion given weekly on days 1, 8 and 15 of a 28 day cycle (up to the maximum number of cycles per local practice)
Drug: paclitaxel
Infusion administered once a week, 3 weeks on and 1 week off

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Median Progression Free Survival
Time Frame: Tumour size assessed at week 8 (±1 week) and then every 8 weeks (±1 week)
PFS is the time from randomisation until the date of objective disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) or death (by any cause in the absence of progression).
Tumour size assessed at week 8 (±1 week) and then every 8 weeks (±1 week)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival : Number of Patients Who Had Died at DCO (Data Cut Off)
Time Frame: Tumour size assessed at week 8 (±1 week) and then every 8 weeks (±1 week)
Tumour size assessed at week 8 (±1 week) and then every 8 weeks (±1 week)
Objective Response Rate
Time Frame: Week 8 (±1 week) and then every 8 weeks (±1 week)
ORR=Percentage of patients with at least one visit response of CR (complete response) or PR (partial response) that is confirmed at least 4 weeks later; CR:disappearance of target lesions and no new lesions; PR is at least 30% decrease in sum of diameters of lesions taking as a reference the smallest sum since treatment started.
Week 8 (±1 week) and then every 8 weeks (±1 week)
Percentage Change From Baseline at Week 8 in Target Lesion Size
Time Frame: Baseline, Week 8 (±1 week)
A negative change denotes a reduction in target lesion size. Percentage change from baseline in tumour size at 8 weeks in target lesion size.
Baseline, Week 8 (±1 week)
Percentage of Patients Without Progressive Disease at 8 Weeks
Time Frame: Week 8 (±1 week)
PD = A ≥ 20% increase in the sum of diameters of target lesions and an absolute increase of ≥ 5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diamters
Week 8 (±1 week)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

  • Study Director: Paul Stockman, MD PHD, AstraZeneca
  • Principal Investigator: Eric Van Cutsem, MD PHD, University Hospital, Gasthuisberg

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2011

Primary Completion (ACTUAL)

August 1, 2013

Study Completion (ACTUAL)

February 1, 2015

Study Registration Dates

First Submitted

September 16, 2011

First Submitted That Met QC Criteria

October 20, 2011

First Posted (ESTIMATE)

October 24, 2011

Study Record Updates

Last Update Posted (ACTUAL)

March 7, 2017

Last Update Submitted That Met QC Criteria

January 16, 2017

Last Verified

January 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • D2610C00004

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe